List view / Grid view
29 July 2015 | By Victoria White
Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin...
15 July 2015 | By Victoria White
Sanofi plans to evolve its business with the creation of five Global Business Units: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.
8 July 2015 | By Victoria White
Sanofi is to extend its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new single, fixed-dose combination therapy for malaria...
9 June 2015 | By Victoria White
Results of the ELIXA study assessing the cardiovascular safety of lixisenatide in adults with type 2 diabetes and high CV risk have been presented...
8 June 2015 | By Victoria White
Sanofi has announced results from two extension studies where participants with diabetes received Toujeo or Lantus treatment for a total of 12 months...
1 June 2015 | By Victoria White
A new study compared the effectiveness of cabazitaxel alone versus cabazitaxel combined with carboplatin in patients with mCRPC...
21 May 2015 | By Victoria White
Phase 3 study of sarilumab met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis...
19 May 2015 | By Victoria White
Regeneron and Sanofi have shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate to-severe asthma, who are uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA).
29 April 2015 | By Victoria White
The EC has granted marketing authorisation in Europe for Sanofi’s Toujeo for the treatment of type 1 and type 2 diabetes mellitus in adults...
24 March 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report...
19 March 2015 | By Victoria White
Sanofi announce top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, comparing lixisenatide to placebo in adults with type 2 diabetes...
26 February 2015 | By Sanofi
The U.S. Food and Drug Administration (FDA) has approved Sanofi's Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes...
3 February 2015 | By Sanofi / MannKind Corporation
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes...
16 January 2015 | By Catalent
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates...
19 November 2014 | By Sanofi / Regeneron Pharmaceuticals
Sanofi and Regeneron Pharmaceuticals, Inc. today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated…
